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Abstract
Neglected tropical diseases cause significant morbidity and mortality and are a source of
poverty in endemic countries. Only a few drugs are available to treat diseases such as leish-
maniasis, Chagas’ disease, human African trypanosomiasis and malaria. Since drug devel-
opment is lengthy and expensive, a drug repurposing strategy offers an attractive fast-track
approach to speed up the process. A set of 100 registered drugs with drug repositioning
potential for neglected diseases was assembled and tested in vitro against four protozoan
parasites associated with the aforementioned diseases. Several drugs and drug classes
showed in vitro activity in those screening assays. The results are critically reviewed and
discussed in the perspective of a follow-up drug repositioning strategy where R&D has to be
addressed with limited resources.
Introduction
Neglected tropical diseases (NTDs) such as leishmaniasis, human African trypanosomiasis and
Chagas’ disease affect the poorest people in developing countries. NTDs are responsible for
substantial global morbidity, mortality and economic losses [1]. Leishmaniasis is endemic in
88 countries around the globe with 350 million people living at risk and there are an estimated
1.5 to 2 million new cases per year [2]. Human African trypanosomiasis is transmitted by tsetse
flies and the disease threatens millions of people in over 20 countries in sub-Saharan Africa.
Due to reinforced surveillance and vector control, the number of reported cases has come
down from approximately 40,000 to less than 8,000 cases in the last 15 years [3]. Chagas’ dis-
ease is endemic in 18 countries in Central and South America. It is estimated that 120 million
people are at risk of infection and that 8 million are already infected [4]. Malaria, caused by
Plasmodium spp., is one of the most devastating diseases in developing countries, with 200 mil-
lion reported cases in 2013, causing 584,000 deaths in that year [5]. There are only a few drugs
available for the treatment of these diseases. These drugs have associated liabilities including
lack of efficacy, severity of side effects, high costs or lack of practicality for field use, all of
which constitute hurdles in terms of access to treatments for patients. To combat these
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neglected tropical diseases, new and better drugs are needed. The next generation of drugs
needs to be effective and safe, orally-available, and with a long shelf-life in tropical field condi-
tions. These drugs should form the basis for simple, short-course drug administration regimens
(maximum 10 days, ideally 1–3 days for malaria) amenable for use in drug combinations, to
prevent the emergence of resistance. The latter demand applies to all diseases but is especially
important for malaria due to the global spread of drug resistance to existing antimalarials
including artemisinin-based derivatives, for which the first cases of delayed clinical efficacy
have already been reported [6].
There are several strategies to develop new drugs against NTDs. De novo drug discovery
and drug development is a highly rational approach but it is a lengthy and expensive process
[7, 8]. Alternatively, a drug repurposing strategy can be used as a fast-track approach guided by
established Target Product Profiles (TPP) [9, 10], but this can only be considered with drugs
which are active in vitro in relevant assays. Existing drugs or drug- like molecules are ideal to
start with, because these molecules often have known pharmacokinetics, safety profile and are
approved by the regulatory authorities [11, 12]. When a new application has been identified,
the molecules can be rapidly advanced into clinical trials. Here, we report the in vitro activity
against Trypanosoma brucei rhodesiense, Leishmania donovani, Trypanosoma cruzi and Plas-
modium falciparum of 100 registered drugs selected for their potential to be repurposed for
antiprotozoal diseases based on their respective TPPs.
Methods
Chemicals
Antiviral compounds were received from the NIH AIDS Reagent Program (USA). Other com-
pounds were purchased from Sigma-Aldrich.
Bioassays
The in vitro activities against the protozoan parasites T. b. rhodesiense, T. cruzi, L. donovani
axenic amastigotes, P. falciparum, and cytotoxicity assessment against L6 cells were determined
in a serial drug dilution assay (100–0.002 μg/ml) as reported in Orhan et al 2010 [13]. Drug
stock solutions (10mg/ml) were in DMSO (100%). The maximal DMSO concentration in the
assays was 0.5%, which does not influence parasite growth. Negative controls did not contain
DMSO. Selectivity index (SI) was calculated as IC50 L6 cells/IC50 parasite.
Activity against Leishmania donovani intracellular amastigotes assay. Mouse peritoneal
macrophages (4 x 104 in 100 μl RPMI 1640 medium containing 10% heat-inactivated FBS)
were seeded into wells of Lab-tek 16-chamber slides. After 24 h 1.2 x 105 amastigote L. dono-
vani in 100 μl were added. The amastigotes were taken from an axenic culture grown at pH 5.4.
Four hours later, the medium containing free amastigote forms was removed and replaced by
fresh medium. The next day the medium was replaced by medium with or without a serial
drug dilution of seven 3-fold dilution steps covering a range from 30 to 0.04 μg/ml. Parasite
growth in the presence of the drug was compared to control wells. After 96 h of incubation, the
medium was removed and the slides fixed with methanol for 10 min followed by staining with
a 10% Giemsa solution. Infected and non-infected macrophages were counted for the control
cultures and those exposed to the serial drug dilutions. The infection rates were determined.
The results were expressed as a percentage reduction in parasite burden compared to control
wells, and the IC50 was calculated by linear regression analysis. The collection of mouse perito-
neal macrophages was done at the Swiss Tropical and Public Health Institute (Basel) according
to the rules and regulations for the protection of animal rights ("Tierschutzverordnung") of the
Drug Repositioning
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Swiss "Bundesamt für Veterinärwesen". The animal work was approved by the veterinary office
of Canton Basel-Stadt, Switzerland (permission number 2374).
In vitro cytotoxicity with mouse peritoneal macrophages. Mouse peritoneal macro-
phages were seeded in 96-well microtitre plates at 104 cells/well in 100 μl RPMI 1640 medium
containing 10% FBS and 2 mM l-glutamine. After 48 h 100 μl fresh medium was added with or
without a serial drug dilution of seven 3-fold dilution steps covering a range from 100 to
0.14 μg/ml. After 96 h of incubation, the plates were inspected under an inverted microscope to
assure sterility. Alamar Blue (20 μl of a solution consisting of 12.5 mg resazurin (Sigma) dis-
solved in 100 ml phosphate buffered saline) was added to each well and the plates incubated
for a further 4 h. The plates were then read with a Spectramax Gemini XS microplate fluorome-
ter (Molecular Devices Cooperation, Sunnyvale, CA, USA) using an excitation wave-length of
536 nm and an emission wavelength of 588 nm. The IC50 values were calculated by linear
regression from the sigmoidal dose inhibition curves using SoftmaxPro software (Molecular
Devices Cooperation, Sunnyvale, CA, USA). Podophyllotoxin was used as control.
T.b.rhodesiense (STIB900) acute mouse model. The STIB900 acute mouse model mimics
the first stage of the disease. Four female NMRI mice were used per experimental group. Each
mouse was inoculated i.p. with 104 bloodstream forms of STIB900, respectively. Heparinized
blood from a donor mouse with approximately 5x106 /ml parasitaemia was suspended in PSG
to obtain a trypanosome suspension of 1×105 /ml. Each mouse was injected with 0.25 ml. Com-
pounds were formulated in 100% DMSO, diluted 10-fold in distilled water. Compound treat-
ment was initiated 3 days post-infection on four consecutive days for all administration routes
(i.p., p.o.) in a volume of 0.1 ml/10 g. Three mice served as infected-untreated controls. They
are not injected with the vehicle alone since we have established in our labs that these vehicles
do not affect parasitaemia nor the mice. Parasitaemia was monitored using smears of tail-snip
blood twice a week after treatment for two weeks followed by once a week until 60 days post-
infection. Mice are considered cured when there is no parasitaemia relapse detected in the tail
blood over the 60-day observation period. Mean relapse days were determined as day of relapse
post-infection of mice. In vivo efficacy studies in mice were conducted at the Swiss Tropical
and Public Health Institute (Basel) according to the rules and regulations for the protection of
animal rights ("Tierschutzverordnung") of the Swiss "Bundesamt für Veterinärwesen". They
were approved by the veterinary office of Canton Basel-Stadt, Switzerland (permission number
739).
Cluster analysis
The drugs selected in this study were clustered according to certain criteria including a) main
indication(s) for which they are registered, b) chemical class and c) mechanisms of action(s).
Whenever possible, the DrugBank classification (http://www.drugbank.ca) was followed to
assign indication as well as mechanism of action labels to the selected drugs. These labels do
not intend to be exhaustive since additional indications as well as mechanisms of action are
known for several of the drugs. Chemical classes were arbitrarily defined according the chemi-
cal scaffolds of the molecules under consideration, with the exception of protease inhibitors
that are better captured under this appellation due to structural variety.
Results and Discussion
A set of 100 registered drugs were collected (S1 Table) in the framework of DNDi exploratory
activities and submitted systematically to a panel of in vitro assays to be profiled for their anti-
protozoal activities. These drugs and drug classes were primarily selected for their potential to
be repurposed provided that in vitro activity could be demonstrated. The inclusion criteria
Drug Repositioning
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comprised a favorable bioavailability profile, moderate cost of goods and a good safety profile.
The selection is heavily biased for anti-infectious indications (66 compounds) including antibi-
otics (26), antifungals (14), antivirals/antiretrovirals (16) as well as antiparasitic compounds
(10) and 15 psychoactive compounds. Another 19 drugs are related to other indications (S1
Table). In some instances drugs were selected based on literature reports of antiprotozoal activ-
ity in relation to one specific molecule or class of compounds. A panel of well-known antipro-
tozoal drugs such as artesunate, mefloquine, pentamidine, nifurtimox and amphotericin B (not
an exhaustive list) were included as benchmarks as well as to cross-profile these drugs in the
entire screening assay panel.
The results (S2 Table) are ranked in agreement with the in vitro activity cutoffs defined at
the hit stage for kinetoplastids [14] and for P. falciparum [15]. Chemical structures and biologi-
cal data sets of all drugs included as part of this research study are available in the
CHEMBL-NTD database https://www.ebi.ac.uk/chemblntd.
Human African trypanosomiasis
Pentamidine and nifurtimox were, unsurprisingly, identified as active against T. b. rhodesiense;
both drugs are used for the treatment of human African trypanosomiasis (HAT) (Table 1, S1
Fig). The mode of action of pentamidine—an aromatic diamidine, a chemical class well-known
for its antitrypanosomal activity—is not fully understood. There is evidence that impairment
of mitochondrial function is involved [16] and that this family of compounds can rapidly accu-
mulate within trypanosomes as demonstrated with DB75 and DB820 [17]. Nifurtimox is a
well-known antitrypanosomal nitrofurane, causing oxidative stress in the target cell [18]. More
recently, the activation of nifurtimox by trypanosomal type I nitroreductases leading to the
generation of cytotoxic nitrile metabolites has been described [19].
Two 5-nitrofuran antibiotics chemically related to nifurtimox (S1 Fig), namely nifuroxazide
(IC50 = 0.03 μM, SI: 410) and nitrofurantoin (IC50 = 0.5 μM, SI: 180) were identified as being
remarkably potent against T. b. rhodesiense (Table 1). The nitrophenylbenzamine niclosamide
showed a lower in vitro activity (IC50 = 1.67 μM), whereas the 5-nitroimidazole derivatives
metronidazole and tinidazole were shown to be inactive in the same assay, presumably because
they are not activated via enzymatic reduction under the experimental conditions. Overall, the
potential for drug repurposing of any nitroheterocycles for HAT heavily depends on their tox-
icity–and notably genotoxicity/mutagenicity—profile in respect to their efficacy in relevant
rodent models, as demonstrated by the successful development of fexinidazole currently in
Phase III clinical trials [20, 21].
Rifamycin SV (IC50 = 0.99 μM, SI: 16) exhibited a selective activity profile against T. b. rho-
desiense (Table 1), whereas other members of the rifamycin family (rifabutin, rifampicin and
rifaximin) were devoid of antitrypanosomal activity. Rifamycins have been used for the treat-
ment of several diseases, the most important being HIV-related tuberculosis. Rifamycin SV is a
semi-synthetic broad-spectrum antibiotic with activity against Gram-positive and Gram-nega-
tive bacteria and mycobacteria. It belongs to the class of ansamycins obtained from rifamycin
B, which is produced by fermentation of Streptomyces mediterranei n. sp. Rifamycin SV is not
readily bioavailable and is used parenterally or topically in the treatment of cutaneous and soft
tissue infections. Rifamycin SV has rather limited penetration into the brain which is a clear lia-
bility for the repositioning of this drug for HAT.
Auranofin showed good and selective activity against T. b. rhodesiense (IC50 = 0.01μM, SI:
479) (S1 Fig). Auranofin is a gold complex used to treat rheumatoid arthritis. It putatively acts
as an inhibitor of kappa B kinase and thioredoxin reductase which would lead to a decreased
immune response and decreased free radical production, respectively [22]. It is a compound
Drug Repositioning
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that targets selenoproteins in the bloodstream and the procyclic form of T. brucei [23]. In a
recent high-throughput drug screen, high activity against Entamoeba was discovered [24].
Auranofin showed 10 times better activity against Entamoeba histolytica than the standard
drug metronidazole. Given the relatively good bioavailability of auranofin (17–23%) as well
as favorable drug exposure in various tissues in rats (terminal half-life of 29 and 43 hours
based on blood and serum levels, respectively) following oral administration of a single dose
(6.7 mg /kg) [25], we performed an in vivo efficacy study in an acutely infected T. bruceimouse
model. However, after daily oral administration of up to 25 mg/kg auranofin over a 4 day
period no in vivo efficacy was observed regarding reduction of parasitemia or increased sur-
vival time (data not presented). This negative outcome could be explained by the lack of a
cidal- mechanism of action, or sub-optimal drug exposure in vivo in mice due to a different
pharmacokinetic profile from that published for rat, or by high protein binding of auranofin.
Table 1. In vitro activity against T.b. rhodesiense in IC50 (μM) of compounds fulfilling hit criteria.
Drug ID aT. b.
rhod.
bCytotox.
L6
cSI Indication Chemical Class Mode of Action
Pentamidine 0.01 8.87 887 Antibacterial/
Antiprotozoal
Dibenzimides Interferes with nuclear synthesis/ interfering agent/
DNA, RNA, phospholipids and protein synthesis
inhibitor
Auranofin 0.01 4.79 479 Antirheumatic Gold agent kappaB kinase and thioredoxin reductase inhibitor
Nifuroxazide 0.03 12.31 410 Antibacterial Nitroheterocycles Lipoamide dehydrogenase inhibition
Nitrofurantoin 0.5 90.31 181 Antibacterial Nitroheterocycles Oxygen-insensitive NADPH nitroreductase
Thioridazine 0.53 5.39 10 Antipsychotic/
Antidepressant
Tricyclics Dopamine D1 and D2 inhibitor
Amphotericin B 0.76 10.27 14 Antifungal/
Antiprotozoal
Polyenes Membrane cell sterol binder
Sertraline 0.77 8.10 11 Antipsychotic/
Antidepressant
Tetrahydro-
napthalenamines
Selective serotonin-reuptake inhibitors
Rifamycin SV 0.99 15.68 16 Antibacterial/
Antituberculotic
Rifamycins bacterial DNA-dependent RNA synthesis inhibitor
Paroxetine 1.13 13.84 12 Antipsychotic/
Antidepressant
Dehydrophenyl-
piperidines
Selective serotonin-reuptake inhibitors
Nortryptyline 1.17 27.87 24 Antipsychotic/
Antidepressant
Tricyclics Serotonin reuptake inhibitor
Triflupromazine 1.42 18.5 13 Antipsychotic/
Antiemetic
Tricyclics Dopamine D1 and D2 receptor inhibitors
Nifurtimox 1.44 87.02 60 Antibacterial/
Antiprotozoal
Nitroheterocycles Induction of oxidative stress in target cell
Clomipramine 2.06 19.79 10 Antipsychotic/
Antidepressant
Tricyclics Serotonin reuptake inhibitor
Promazine 2.16 30.06 14 Antipsychotic/
Antidepressant
Tricyclics Dopamine, serotonine, alpha1 and histamine receptor
inhibitor
Amitriptyline 3.03 42.18 14 Antipsychotic/
Antidepressant
Tricyclics Norepinephrine and serotonin reuptake inhibitor
Chloroquine 3.81 50.61 13 Antimalarial Quinolines Heme polymerase inhibitor
Pizotifen 3.99 45.02 11 Antimigraine Tricyclics serotonin receptor antagonist
aT. b. rhod.:T. b. rhodesiense strain STIB 900, trypomastigotes.
bCytotoxicity on L6 cells.
cSelectivity index: IC50 Cytotoxicity L6/ IC50 T. b. rhodesiense.
IC50 values are means of two independent assays, which varied < ±50%.
doi:10.1371/journal.pone.0135556.t001
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Two adamantane derivatives were tested one of which, rimantadine, acted selectively (IC50
= 13.83 μM SI: 23) against T. b. rhodesiense, albeit at a moderate level. The activity of rimanta-
dine and of other adamantane derivatives against T.brucei has already been reported by Kelly
et al. in 1999 and 2001 [26, 27] and Zoidis et al. 2008 [28]. Ademantanes presumably target
essential T. bruceimembrane-localized ion channels or transporters [29, 30]. Adamantanes are
inexpensive, orally active drugs [31]. They exhibit steady-state levels in serum of 2.5 to 5.0 μM
and plasma half-lives of 24 to 36 hours in humans [32, 33]. Furthermore, adamantanes readily
cross the blood-brain barrier [34]. As such adamantanes, and more particularly the T. brucei
active rimantadine, seem to offer promising potential in terms of drug repurposing for HAT,
although the moderate in vitro potency of rimantadine might be insufficient to demonstrate
efficacy in vivo given the aforementioned serum levels. Adamantanes may therefore be prefera-
bly pursued as part of a lead optimization program to increase potency against T. brucei. A lim-
ited evaluation of 17 adamantanes supported this approach as the most active derivative
(1-adamantyl-4-amino-cyclohexane) was about 20 to 25 times more effective than rimantadine
[27]. The same study delivered the first proof of principle of efficacy of adamantanes in vivo,
with a transient 98% suppression of parasitemia in mice with an acute T. brucei infection.
These encouraging results seem to indicate that lead optimization might be more promising
than a repurposing strategy for this class of compounds.
A key feature of the TPP in curing the second stage of HAT is CNS penetration [9]. Psycho-
active compounds by definition cross the blood-brain barrier. All antidepressant and antipsy-
chotic drugs–including tricyclics and selective serotonin reuptake inhibitors—displayed IC50
values in the range of 0.5–2 μM (Table 1) against T. b. rhodesiense, as well as a limited selectiv-
ity window with respect to the L-6 rat myoblast cell line apart from nortriptyline (SI> 20) (S2
Fig). These drugs act in various ways and levels on dopaminergic and serotoninergic central
receptors indicating that they all have the potential to cross the blood brain barrier. The related
drugs thioridazine, triflupromazine, promazine and chlorpromazine are D2 dopamine receptor
antagonists and Ca2+ channel blockers. Nortriptyline inhibits reuptake of norepinephrine and
is a strong antagonist of the H1 receptor. It is also known as a Na
+ channel blocker. There were
earlier attempts to develop tricyclic compounds as trypanothione reductase inhibitors via lead
optimization efforts [35, 36]. However no clear relationship between the activities measured on
trypanothione reductase and the T. brucei whole cell assay could be drawn from a series of 22
inhibitors [36]. It is, to our knowledge, the first time that selective serotonin reuptake inhibitors
(including sertraline and paroxetine) are reported to show activity against T. b. rhodesiense.
The poly-pharmacology profile of these drugs, notably with respect to associated central effects
and toxicity will have to be carefully considered in the light of dose findings in mouse models.
Chagas’ disease
Not surprisingly nitroheterocycles, in particular nitrofurane derivatives including nifurtimox,
nifuroxazide and nitrofurantoin, exhibited the highest antichagasic activity (Table 2, S3 Fig).
Nitrofuranes are well known for their antichagasic activity: Nifurtimox—as well as benznida-
zole, the second treatment available for Chagas’ disease- has been shown to be activated by a
NADH-dependent, mitochondrially localized type I nitroreductase [37]. A repurposing strat-
egy for any nitrofurans or nitroimidazole analogues including nifuroxazide and nitrofuran-
toin, must be based primarily on the safety profile compared to currently used drugs. This
notably includes genotoxicity/mutagenicity as previously mentioned in the case of human
African trypanosomiasis. In addition, any compound should demonstrate equivalent or bet-
ter in vitro activity and in vivo efficacy than the current drugs. Interestingly, another com-
pound from the nitroimidazole class–fexinidazole—has recently also been reported for its
Drug Repositioning
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oral efficacy in acute and chronic experimental models of benznidazole-susceptible, partially
resistant, or resistant T. cruzi isolates [38] and could therefore be considered as a good candi-
date for drug repositioning.
Azoles were identified as the most potent class of inhibitors: six representatives had IC50 val-
ues in the range of 0.003–0.3 μM and SI:>100 (bifonazole, clotrimazole, econazole nitrate,
miconazole and tioconazole as imidazoles as well as itraconazole and ketoconazole as triazoles)
while other compounds from this class displayed lower activity and/or selectivity against
T. cruzi (Table 2). These well-known antifungal drugs are already known for their activity
against T. cruzi and for acting via inhibition of 14-alpha-sterol demethylase, an enzyme of the
sterol biosynthesis pathway [39]. Two triazole antifungals, posaconazole and E1224 (a prodrug
of ravuconazole), have recently been reported as failing to demonstrate sustained clearance of
T. cruzi parasitemia in chronically infected patients in phase II clinical trials, putting azoles as a
therapeutic class at stake for the treatment of Chagas’disease, at least in monotherapy [40].
This outcome might well be correlated with the inability of azoles and of non-azole CYP51
inhibitors to achieve parasite clearance in vitro in various T. cruzi lineages [41].
Two other compounds that showed moderate micromolar in vitro activity against T. cruzi
were tadalafil (IC50 = 8.6 μM SI:>26) and mebeverine (IC50 = 3.89 μM SI: 18) (Table 2, S3
Fig). Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor used in treating erectile dysfunc-
tion. PDEs are cAMP-specific hydrolases and play a major role in cyclic nucleotide signaling
[42]. One of the main challenges to be considered in terms of drug repurposing of PDE inhibi-
tors relates to the safety profile associated with the structural similarity between the human
and protozoan PDE. However, the recently identified parasite-specific pocket (P-pocket) in the
enzymes of T.cruzi, L.major and T.brucei which is close to the active site might allow the
design of parasite-specific inhibitors [43, 44].
Table 2. In vitro activity against T. cruzi in IC50 (μM) of compounds fulfilling hit criteria.
Drug ID aT.
cruzi
bCytotox.
L6
cSI Indication Chemical Class Mode of Action
Bifonazole 0.003 39.30 >1000 Antifungal Azoles 14alpha-sterol demethylase inhibitor
Itraconazole 0.004 1.11 278 Antifungal Azoles 14alpha-sterol demethylase inhibitor
Clotrimazole 0.006 2.99 498 Antifungal Azoles 14alpha-sterol demethylase inhibitor
Miconazole 0.04 15.44 383 Antifungal Azoles 14alpha-sterol demethylase inhibitor
Econazole 0.04 15.60 390 Antifungal Azoles 14alpha-sterol demethylase inhibitor
Tioconazole 0.064 19.47 304 Antifungal Azoles 14alpha-sterol demethylase inhibitor
Ketoconazole 0.27 50.99 189 Antifungal Azoles 14alpha-sterol demethylase inhibitor
Fluconazole 9.96 >294 >30 Antifungal Azoles 14alpha-sterol demethylase inhibitor
Nifurtimox 0.19 87.02 458 Antibacterial/
Antiprotozoal
Nitroheterocycles Induction of oxidative stress in target cell
Nifuroxazide 0.23 12.31 54 Antibacterial Nitroheterocycles Lipoamide dehydrogenase inhibition
Nitrofurantoine 4.35 90.31 21 Antibacterial Nitroheterocycles Oxygen-insensitive NADPH nitroreductase
Mebeverine 3.89 70.77 18 Antispasmotic Phenylbenzoates serotonin 5-HT3 receptor antagonist
Tadalafil 8.60 221.1 26 Erectile dysfunction Pyridoiindolediones cGMP-specific 3',5'-cyclic phosphodiesterase
inhibitor
aT. cruzi, strain Tulahuen C4, intracellular amastigotes.
bCytotoxicity on L6 cells.
cSelectivity index: IC50 Cytotoxicity L6/ IC50 T. cruzi.
IC50 values are means of two independent assays, which varied < ±50%.
doi:10.1371/journal.pone.0135556.t002
Drug Repositioning
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The antispasmodic mebeverine is used for the treatment of irritable bowel syndrome (IBS)
and associated abdominal cramping. It works by relaxing the muscles in and around the gut.
Mebeverine is also a functional inhibitor of acid sphingomyelinase (FIASMA) [45] as well as a
serotonin 5-HT3 receptor antagonist. To our knowledge this is the first time that tadalafil and
mebeverine are reported to have antichagasic properties. Even if the antitrypanosomal activity
is moderate, a more careful evaluation of their activity needs to be conducted to better under-
stand their potential for drug repositioning for Chagas’ disease.
Leishmaniasis
All selected candidates were tested in two different assays, involving axenic amastigotes and
intracellular amastigotes of L. donovani, respectively. The latter assay used peritoneal mouse
macrophages as host cells. Amastigotes in macrophages are currently considered to be more
relevant for the visceral disease pathology than axenic amastigotes [46]. For cytotoxicity the
compounds were counter-screened against non-infected peritoneal mouse macrophages. Apart
from amphotericin B and sitamaquine that can be considered as control drugs in this screen-
ing, clofazimine was the only compound exhibiting activity in the Leishmania donovani intra-
cellular assay as well as an acceptable level of selectivity (SI*10) (Table 3, S4 Fig).
Amphotericin B is a polyene antifungal drug displaying either fungistatic or fungicidal activity
depending on the drug concentration in body fluids with respect to the susceptibility of the
investigated fungal microorganism. The liposomal formulation of amphotericin B (marketed
as AmBisome) is currently used as monotherapy for the treatment of visceral leishmaniasis.
Amphotericin B binds irreversibly to ergosterol, resulting in disruption of membrane integrity
and leakage of intracellular components leading to cell death [47].
Sitamaquine, a known antileishmanial drug, displayed only moderate activity against both
axenic and intracellular amastigotes (Table 3). The drug development of sitamaquine was dis-
continued in Phase II clinical trials by GlaxoSmithKline due to safety concerns related to
methemoglobinemia, a known feature of 8-aminoquinolines [48].
Clofazimine is a lipophilic riminophenazine derivative possessing both antimycobacterial
and anti-inflammatory properties. Its efficacy has been demonstrated in the treatment of lep-
rosy only in combination with rifampicin and dapsone, but not in human tuberculosis, despite
the fact that it is impressively active in vitro against multidrug-resistant strains ofMycobacte-
rium tuberculosis [49]. Interestingly, clofazimine is more active against intracellular than axenic
Leishmania donovani, putatively due to the accumulation of clofazimine in the macrophages, a
known feature of riminophenazines [50]. The antileishmanial properties of clofazimine have
previously been reported both in vitro and in animal models for three different Leishmania
species including L. donovani [51]. Clofazimine binds to guanine bases leading to an inhibition
of cell proliferation [52]. Additionally, clofazimine inhibits acid sphingomyelinase (FIASMA)
and increases the activity of phospholipase A2 [47]. Cell membrane destabilization and subse-
quent dysfunction as well as intracellular redox cycling involving oxidation of reduced clofazi-
mine leading to the generation of reactive oxygen species were proposed as mechanisms
contributing to the antimycobacterial activity of clofazimine. These putative mechanisms of
action have recently been reviewed by Cholo et al. 2012 [49]. Considering the very good phar-
macokinetic, distribution and safety profiles of clofazimine in the mouse [50] it seems quite
reasonable to envisage an in vivo efficacy study of this drug in a relevant mouse model infected
with Leishmania donovani.
Tipranavir (a non-peptidic protease inhibitor [53]), the antimalarial artesunate and other
antibacterials like nitrofurantoine, nifuroxazide, rifampicin and rifamycin SV were all active
(IC50:< 3μM) against axenic amastigotes of L. donovani, but inactive against the intracellular
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amastigotes or cytotoxic on the host cell (Table 3). Auranofin was active against axenic amasti-
gotes (IC50 = 0.11μM). But auranofin did not exhibit activity against intracellular amastigotes
at a concentration of 1.47 μM and at 4.42 μM it was cytotoxic on the host cells. This is some-
what contradictory to published data [54], which however used different Leishmaia species and
a different host cell. The hydroxypyridinone antifungal ciclopirox olamine showed activity
against axenic amastigotes and activity against intracellular amastigotes of L. donovani (IC50 =
0.1 μM, SI: 9) with moderate selectivity (Table 3, S4 Fig). In addition, the two azoles clotrima-
zole and tioconazole were active with low selectivity against intracellular L. donovani (S1
Table). Niclosamide used as an anthelmintic, in addition to auranofin, showed the best activity
of all tested compounds against L. donovani axenic amastigotes but it was inactive against
intracellular amastigotes at a concentration of 0.1 μg/ml, and toxic to mouse macrophages at
higher concentrations (>0.3 μg/ml) (S1 Table). The repurposing potential of these few drugs
Table 3. In vitro activity against L. donovani in IC50 (μM) of compounds fulfilling hit criteria.
Drug ID aL.
don.
axen.
bL. don.
intracell
cCytotox.
mac.inf.
dCytotox.
PMM
eSI Indication Chemical Class Mode of Action
Auranofin 0.11 >1.47 4.42 N/A 40 Antirheumatic Gold agent kappaB kinase and thioredoxin
reductase inhibitor
Amphotericin B 0.34 0.31 32.4 22.39 95 Antifungal/
Antiprotozoal
Polyenes Membrane cell sterol binder
Ciclopirox
olamine
1.64 9.09 20.3 20.27 12 Antifungal Pyridinones Polyvalent metal cation chelator
Tolnaftate 4.33 50.1 97.6 N/A >23 Antifungal Thiocarbamates Squalene epoxidase inhibitor
Artesunate 0.35 >7.8 7.8 N/A >22 Antimalarial Endoperoxides Unknown, acting via reactive
oxygen radical species
Rifamycin SV 1.5 >13.87 41.62 N/A 28 Antibacterial/
Antituberculotic
Rifamycins bacterial DNA-dependent RNA
synthesis inhibitor
Rifampicin 1.53 >36.45 36.5 N/A >24 Antibacterial/
Antituberculotic
Rifamycins Bacterial DNA-dependent RNA
synthesis inhibitor
Nitrofurantoine 2.12 >41.81 125.44 N/A 59 Antibacterial Nitroheterocycles Oxygen-insensitive NADPH
nitroreductase
Nifurtimox 2.76 20.68 34.8 15.7 13 Antibacterial/
Antiprotozoal
Nitroheterocycles Induction of oxidative stress in
target cells
Troglitazone 4.26 >67.94 68 N/A >16 Antidiabetic/
Antinflammatory
Thiazolidinediones Nuclear receptor (PPAR) binder
Clofazimine 22.39 0.95 6.34 10.65 10 Antibacterial/
Antituberculotic
Riminophenazines Mycobacterial DNA binder, Redox
cycling, Cell membrane
destabilizer, Acid
sphingomyelinase inhibitor
Nifuroxazide 2.83 >10.86 36.2 N/A 13 Antibacterial Nitroheterocycles Lipoamide dehydrogenase
inhibition
Tipranavir 1.64 >49.78 50 N/A >30 Antiviral/
Antiretroviral
Protease
Inhibitors
HIV protease inhibitor
Lonidamine 8.66 >93.41 93.4 N/A >11 Anticancer Indazoles Glycolysis inhibition via
hexokinase activation
aL. don. axen.: axenic amastigotes of L. donovani, strain MHOM-ET-67/L82.
bL. don. intracell: intracellular amastigotes of L. donovani strain MHOM-ET-67/L82.
cCytotoxicity on macrophages infected with L. donovani.
dCytotoxicity on peritoneal mouse macrophages.
eSelectivity index: IC50 Cytotoxicity macrophages/ IC50 L. donovani. IC50 values are means of two independent assays, which varied < ±50%.
doi:10.1371/journal.pone.0135556.t003
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seems rather low as they were either not able to demonstrate any significant activity in the
intracellular L. donovani assay or alternatively lacked selectivity.
Malaria
The in vitro activity of all of the tested standard animalarials (artesunate, mefloquine, tafeno-
quine, chloroquine and sitamaquine) was confirmed against P. falciparum as shown in Table 4.
Interestingly, four of the tested azoles (clotrimazole, econazole, miconazole and tioconazole)
were active against P. falciparum (Table 4, S5 Fig) confirming the finding of Penna Coutinho
et al. 2011 [55] who described the antimalarial activity of posaconazole and itraconazole.
Rifamycins, especially rifampicin (IC50 = 0.1 μM, SI:>100), showed remarkably selective
activity in the antiplasmodial assay (Table 4). The anti-tuberculosis drug rifampicin is an RNA
polymerase inhibitor of bacterial transcription and was previously described for its in vitro and
Table 4. In vitro activity against P. falciparum in IC50 (μM) of compounds fulfilling hit criteria.
Drug ID aP. falc.
K1
bCytotox.
L6
cSI Indication Chemical Class Mode of Action
Mefloquine 0.002 3.25 1354 Antimalarial Quinolines Unknown, putative heme polymerase inhibitor
Artesunate 0.003 0.78 260 Antimalarial Endoperoxides Unknown, acting via reactive oxygen radicals
Chloroquine 0.17 50.61 298 Antimalarial Quinolines Heme polymerase inhibitor
Tafenoquine 0.27 5.52 20 Antimalarial Quinolines Unknown, putative heme polymerase inhibitor
Sitamaquine 0.08 32.31 404 Antileishmanial Quinolines Unknown
Rifampicin 0.1 75.22 752 Antibacterial/
Antituberculotic
Rifamycins Bacterial DNA-dependent RNA synthesis
inhibitor
Rifamycin SV 0.55 15.68 29 Antibacterial/
Antituberculotic
Rifamycins bacterial DNA-dependent RNA synthesis
inhibitor
Rifaximin 0.92 88.05 96 Antibacterial/
Antituberculotic
Rifamycins Bacterial DNA-dependent RNA synthesis
inhibitor
Amphotericin
B
0.8 10.27 13 Antifungal/Antiprotozoal Polyenes Membrane cell sterol binder
Clotrimazole 0.11 2.99 27 Antifungal Azoles 14alpha-sterol demethylase inhibitor
Econazole 0.32 15.6 49 Antifungal Azoles 14alpha-sterol demethylase inhibitor
Miconazole 0.49 15.44 32 Antifungal Azoles 14alpha-sterol demethylase inhibitor
Tioconazole 0.63 19.47 31 Antifungal Azoles 14alpha-sterol demethylase inhibitor
Promazine 0.49 30.06 61 Antipsychotic/
Antidepressant
Tricyclics Dopamine, serotonin, alpha1 and histamine
receptor inhibitor
Fluphenazine 0.50 11.54 23 Antipsychotic/
Antidepressant
Tricyclics Dopamine receptor inhibitor
Sertraline 0.51 8.10 16 Antipsychotic/
Antidepressant
Tetrahydro-
napthalenamines
Selective serotonin-reuptake inhibitors
Nortryptyline 0.58 27.87 48 Antipsychotic/
Antidepressant
Tricyclics Serotonin reuptake inhibitor
Ketotifen 0.75 147.04 196 Antihistamine Cycloheptathio-
phenones
H1-Histamine receptor antagonist
Cloperastine 0.87 43.35 50 Cough Suppressant Phenylmethoxy-
piperidines
Unknown
Rimantadine 0.97 311.2 321 Antiviral/Antiretroviral Adamantanes Matrix protein 2 inhibitor
aP. falc.: P. falciparum strain K1.
bCytotoxicity on L6 cells.
cSelectivity index: IC50 Cytotoxicity L6/ IC50 P. falciparum.
IC50 values are means of two independent assays, which varied < ±50%.
doi:10.1371/journal.pone.0135556.t004
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in vivo antimalarial activities [56, 57]. To our knowledge, other compounds from this class
have not been reported to have antimalarial activity.
The antiplasmodial activity associated with tricyclic antidepressants (Table 4, S5 Fig) is cer-
tainly one of the most striking observations of this screen. Promazine and nortriptyline dis-
played the highest selective activity against P. falciparum. Promazine is a phenothiazine
compound and a D2 dopamine receptor antagonist which showed an IC50 value of 0.49 μM
with a selectivity index of 61. Nortriptyline, a tricyclic antidepressant and potent inhibitor of
the norepinephrine transporter exhibited an IC50 value of 0.58 μM against P. falciparum, and a
selectivity index of 48. Tricyclic antidepressant drugs have previously been shown to reverse
chloroquine resistance in P. falciparum in vitro and in monkey studies [58].and were addition-
ally described in a recent publication as blocking agents for Plasmodium oocyst development
and transmission [59]. Transmission blocking is an important feature for the elimination of
malaria. It is worth noting that further tricyclics (including fluphenazine and amitriptyline) as
well as selective serotonin reuptake inhibitors (sertraline and fluoxetine) also displayed anti-
plasmodial activities in the micromolar range. Additionally, in vitro selective activities against
P. falciparum were identified for the antiviral rimantadine, the anti-thrombotic dipyridamole,
the anti-tussive clopersatine, and the anti-histamine ketotifen. All of these activities have
already been reported elsewhere [60, 61]. Providing a cidal mechanism of action can be con-
firmed for these drugs, the next step will consist of an evaluation of their potential to suppress
parasitemia in a mouse malaria model. If successful, the repurposing potential of these drugs
will need to be carefully assessed considering the safety profile at the defined curative dose,
notably in relation to the pharmacological effects of these drugs at the dosing regimen used.
This constitutes a major challenge, especially for the drugs for which there is a dramatic dis-
crepancy in terms of in vitro activities between their primary indication (generally 1–10 nM
range) and malaria (100 nM-1μM range). The compatibility of these drugs with a short (1–3
day) oral treatment, their low susceptibility to generate resistance, and their amenability for use
in combination with existing antimalarial drugs will similarly need to be considered.
Conclusion
Several drugs and drug classes were confirmed to have in vitro activity against the four proto-
zoan parasites T. brucei rhodesiense, L. donovani, T. cruzi and P. falciparum, offering various
opportunities for drug repurposing. Several of these antiparasitic activities–but not all- have
already been reported. To our knowledge it is indeed the first time that tadalafil and mebever-
ine have been described for their antichagasic activity. For these drugs a wealth of preclinical
and clinical data can be used to determine whether their safety profiles are compatible with the
anticipated dose of drug to be used in animal models and eventually in patients. The candidates
for further development should ideally be associated with a favorable bioavailability profile, as
oral drug administration is preferable for the next generation of drugs used to treat kinetoplas-
tid diseases. The reasons for a lack of or insufficient in vivo efficacy in relevant preclinical ani-
mal models shall be further investigated to assist in the decision to drop or further pursue an
existing drug for repurposing. There is a clear need to carefully define the types of preclinical
experiments that need to be run to progress the candidates identified from screening in the
framework of a defined drug discovery cascade supported by DMPK and toxicity assays.
Drug repurposing is a discovery strategy that aims to maximise pre-existing preclinical and
clinical knowledge accumulated on registered drugs and drug candidates for a new indication
[12], and is nowadays actively pursued by pharmaceutical companies [62] and currently
accounts for approximately 30% of the newly approved drugs and vaccines by the US Food and
Drug Administration—in recent years [63]. The area of neglected diseases has counted for a
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few drug repositioning successes such as the antibacterial sulfonamides (dapsone, sulfadoxine),
tetracyclines (doxycycline) and combination of trimethoprim/sulfamethoxazole for malaria
[64], fluoroquinolones for tuberculosis [64], and the anticancer agent miltefosine as well as the
antifungal amphotericin B for the treatment of visceral leishmaniasis [65].
Several approaches can be used to address the identification of novel drug candidates at an
early discovery stage using a drug repositioning approach. They notably include target-based
screening, phenotypic (“target unbiased or blinded”) screening, knowledge-based methods
(e.g. chemoinformatics and bioinformatics), signature-based methods, pathway or network
methods and targeted mechanism-based methods, reviewed and illustrated elsewhere [63].
From a recent comparative analysis based on 259 approved agents [66], 50 were shown to be
first-in-class small molecules associated with a new molecular mechanism of action, of which
28 and 17 of these drugs were identified from phenotypic screening and target-based
approaches, respectively. These results illustrate the impressive potential of phenotypic screen-
ing in the area of drug discovery. The screening of a library of drugs and drug candidates in a
phenotypic assay is therefore seen as an attractive way to identify new potential candidates
with a modest work load. This can be illustrated by the discovery of the antimalarial properties
of astemizole from the screening of 2687 approved drugs or drug candidates using a P. falcipa-
rum whole cell in vitro screening assay [67].
In summary, this low-hanging fruit approach is certainly worth the effort in a “low risk,
high return on investment” drug discovery process, especially in the field of neglected tropical
diseases where R&D has to be addressed with limited resources. The availability of a significant
amount of data and expertise can indeed lead to significant savings in terms of time and
money. Some of the approved marketed drugs will have the additional advantage of being off-
patent, facilitating the drug repurposing process from an intellectual property management
standpoint. A drawback related to the progression of old drugs might however be the lack or
the paucity of recently generated data reports (e.g. lack of quality of pharmacokinetic measure-
ments based on LC/MS, and toxicity assays performed in obsolete in vitro and in vivo predic-
tive models).
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